About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2018-11-26
Henlius HLX22 Received IND Application Acceptance Notification from NMPA
2018-11-16
Henlius Successfully Held Its Second Scientific Advisory Board (SAB) Meeting in California
2018-11-01
Cooperation Upgrades! Henlius Has been Granted to Develop and Commercialize AC101 in the World
2018-10-26
New Progress! Henlius Received Clinical Approval for Its Anti-VEGFR2 Monoclonal Antibody, HLX12
2018-10-18
Henlius Nominated for the Global Generics & Biosimilars Awards 2018 in Two Categories
2018-09-10
Important News! Henlius Combination Therapy Received Approval to Conduct Clinical Trials in China
2018-08-09
Henlius Submitted Investigational New Drug Application for Its HLX12
2018-06-21
Henlius and Accord Entered into an License Agreement for HLX02
2018-06-04
Henlius will Initiate Phase I Clinical Trialof HLX20 (Anti-PD-L1 Antibody) in Australia
1
...
35
36
37
38
39